Last reviewed · How we verify
NCT05617794: ASH-2
Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness
NA trial testing Diffusion Optics Technology (DOT) Pattern Spectacle Lens in Myopia in 30 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2023
Quick facts
| Lead sponsor | SightGlass Vision, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 18 January 2023 |
| Primary completion | 30 April 2023 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Diffusion Optics Technology (DOT) Pattern Spectacle Lens
- Control Spectacle Lens
Conditions studied
- Myopia — all drugs for Myopia →
- Myopia Progression — all drugs for Myopia Progression →
- Juvenile Myopia — all drugs for Juvenile Myopia →
Sponsor
SightGlass Vision, Inc.
Who can join
Adults 8 to 14, any sex, with Myopia or Myopia Progression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of Lag of Accommodation with Full-Field Diffusion Optics Technology™ (DOT) Contrast Management Spectacle Lenses in Emmetropic Children.
Jabeen A, Luensmann D, Woods J, Hill JS, et al · · 2024 · cited 1× · PMID 38711574 · DOI 10.2147/opth.s453790
Verify or expand the search:
- PubMed search for NCT05617794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia
Currently open trials in the same condition.
- NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
- NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
- NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
Other SightGlass Vision, Inc. trials
Trials by the same sponsor.
- NCT07229352 — Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses · NA · not yet recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
- NCT07008001 — Assessment of DOT Spectacles in Chinese Children Extension · NA · recruiting
- NCT06034327 — Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens · NA · recruiting
- NCT05893979 — Myopia Control Spectacle Lens Cessation Study · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05617794 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SightGlass Vision, Inc.
- Last refreshed: 20 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05617794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing